Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
23
RMTI Quote, Financials, Valuation and Earnings
Last price:
$0.81
Seasonality move
:
14.03%
Day range:
$0.78 - $0.81
52-week range:
$0.78 - $2.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.37x
P/B ratio:
0.86x
Volume:
246.9K
Avg. volume:
268K
1-year change:
-62.36%
Market cap:
$31.9M
Revenue:
$101.5M
EPS (TTM):
-$0.16
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RMTI
Rockwell Medical, Inc.
|
$16.2M | $0.01 | -32.91% | -- | $3.75 |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
HUMA
Humacyte, Inc.
|
$922.8K | -$0.15 | 58.22% | -15.1% | $7.86 |
|
NUWE
Nuwellis, Inc.
|
$2.1M | -- | -0.52% | -- | $13.00 |
|
PAVM
PAVmed, Inc.
|
$12.5K | -$0.20 | -100% | -78.99% | $9.50 |
|
TLSI
TriSalus Life Sciences, Inc.
|
$11.8M | -$0.17 | 55.01% | -67.11% | $11.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RMTI
Rockwell Medical, Inc.
|
$0.81 | $3.75 | $31.9M | -- | $0.00 | 0% | 0.37x |
|
CRMD
CorMedix, Inc.
|
$12.19 | $19.00 | $960.4M | 5.94x | $0.00 | 0% | 4.10x |
|
HUMA
Humacyte, Inc.
|
$1.08 | $7.86 | $202.3M | -- | $0.00 | 0% | 98.39x |
|
NUWE
Nuwellis, Inc.
|
$2.06 | $13.00 | $14.3M | -- | $0.00 | 0% | 0.55x |
|
PAVM
PAVmed, Inc.
|
$0.29 | $9.50 | $7.9M | 0.30x | $0.00 | 0% | 256.11x |
|
TLSI
TriSalus Life Sciences, Inc.
|
$7.06 | $11.50 | $352.7M | -- | $0.00 | 0% | 5.80x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RMTI
Rockwell Medical, Inc.
|
26.17% | 1.818 | 27.76% | 3.34x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
HUMA
Humacyte, Inc.
|
110.37% | 6.119 | 18.3% | 0.81x |
|
NUWE
Nuwellis, Inc.
|
8.91% | -1.959 | 1.64% | 1.20x |
|
PAVM
PAVmed, Inc.
|
20.6% | 0.050 | 34.03% | 0.30x |
|
TLSI
TriSalus Life Sciences, Inc.
|
461.2% | -0.594 | 14.71% | 2.54x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RMTI
Rockwell Medical, Inc.
|
$2.3M | -$1.6M | -12.07% | -17.16% | -9.95% | -$1.5M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
HUMA
Humacyte, Inc.
|
-$1.4M | -$24.4M | -84.37% | -- | -3239.04% | -$24M |
|
NUWE
Nuwellis, Inc.
|
$1.4M | -$2.7M | -773.58% | -1004.06% | -121.65% | -$3.2M |
|
PAVM
PAVmed, Inc.
|
-$72K | -$4.8M | 4.06% | 8.75% | -96880% | -$899K |
|
TLSI
TriSalus Life Sciences, Inc.
|
$9.7M | -$9M | -936.41% | -- | -77.94% | -$3.9M |
Rockwell Medical, Inc. vs. Competitors
-
Which has Higher Returns RMTI or CRMD?
CorMedix, Inc. has a net margin of -11.01% compared to Rockwell Medical, Inc.'s net margin of 49.9%. Rockwell Medical, Inc.'s return on equity of -17.16% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital RMTIRockwell Medical, Inc.14.27% -$0.05 $50.1M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About RMTI or CRMD?
Rockwell Medical, Inc. has a consensus price target of $3.75, signalling upside risk potential of 363.36%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 55.87%. Given that Rockwell Medical, Inc. has higher upside potential than CorMedix, Inc., analysts believe Rockwell Medical, Inc. is more attractive than CorMedix, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RMTIRockwell Medical, Inc.1 0 0 CRMDCorMedix, Inc.4 0 0 -
Is RMTI or CRMD More Risky?
Rockwell Medical, Inc. has a beta of 1.621, which suggesting that the stock is 62.123% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock RMTI or CRMD?
Rockwell Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rockwell Medical, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RMTI or CRMD?
Rockwell Medical, Inc. quarterly revenues are $15.9M, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Rockwell Medical, Inc.'s net income of -$1.8M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Rockwell Medical, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 5.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rockwell Medical, Inc. is 0.37x versus 4.10x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RMTIRockwell Medical, Inc.0.37x -- $15.9M -$1.8M CRMDCorMedix, Inc.4.10x 5.94x $104.3M $108.6M
-
Which has Higher Returns RMTI or HUMA?
Humacyte, Inc. has a net margin of -11.01% compared to Rockwell Medical, Inc.'s net margin of -2325.37%. Rockwell Medical, Inc.'s return on equity of -17.16% beat Humacyte, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RMTIRockwell Medical, Inc.14.27% -$0.05 $50.1M HUMAHumacyte, Inc.-182.21% -$0.11 $45.8M -
What do Analysts Say About RMTI or HUMA?
Rockwell Medical, Inc. has a consensus price target of $3.75, signalling upside risk potential of 363.36%. On the other hand Humacyte, Inc. has an analysts' consensus of $7.86 which suggests that it could grow by 627.51%. Given that Humacyte, Inc. has higher upside potential than Rockwell Medical, Inc., analysts believe Humacyte, Inc. is more attractive than Rockwell Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RMTIRockwell Medical, Inc.1 0 0 HUMAHumacyte, Inc.5 1 0 -
Is RMTI or HUMA More Risky?
Rockwell Medical, Inc. has a beta of 1.621, which suggesting that the stock is 62.123% more volatile than S&P 500. In comparison Humacyte, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RMTI or HUMA?
Rockwell Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Humacyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rockwell Medical, Inc. pays -- of its earnings as a dividend. Humacyte, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RMTI or HUMA?
Rockwell Medical, Inc. quarterly revenues are $15.9M, which are larger than Humacyte, Inc. quarterly revenues of $753K. Rockwell Medical, Inc.'s net income of -$1.8M is higher than Humacyte, Inc.'s net income of -$17.5M. Notably, Rockwell Medical, Inc.'s price-to-earnings ratio is -- while Humacyte, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rockwell Medical, Inc. is 0.37x versus 98.39x for Humacyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RMTIRockwell Medical, Inc.0.37x -- $15.9M -$1.8M HUMAHumacyte, Inc.98.39x -- $753K -$17.5M
-
Which has Higher Returns RMTI or NUWE?
Nuwellis, Inc. has a net margin of -11.01% compared to Rockwell Medical, Inc.'s net margin of 21.11%. Rockwell Medical, Inc.'s return on equity of -17.16% beat Nuwellis, Inc.'s return on equity of -1004.06%.
Company Gross Margin Earnings Per Share Invested Capital RMTIRockwell Medical, Inc.14.27% -$0.05 $50.1M NUWENuwellis, Inc.65.18% $0.56 $4.3M -
What do Analysts Say About RMTI or NUWE?
Rockwell Medical, Inc. has a consensus price target of $3.75, signalling upside risk potential of 363.36%. On the other hand Nuwellis, Inc. has an analysts' consensus of $13.00 which suggests that it could grow by 22327.21%. Given that Nuwellis, Inc. has higher upside potential than Rockwell Medical, Inc., analysts believe Nuwellis, Inc. is more attractive than Rockwell Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RMTIRockwell Medical, Inc.1 0 0 NUWENuwellis, Inc.0 1 0 -
Is RMTI or NUWE More Risky?
Rockwell Medical, Inc. has a beta of 1.621, which suggesting that the stock is 62.123% more volatile than S&P 500. In comparison Nuwellis, Inc. has a beta of -0.165, suggesting its less volatile than the S&P 500 by 116.484%.
-
Which is a Better Dividend Stock RMTI or NUWE?
Rockwell Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rockwell Medical, Inc. pays -- of its earnings as a dividend. Nuwellis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RMTI or NUWE?
Rockwell Medical, Inc. quarterly revenues are $15.9M, which are larger than Nuwellis, Inc. quarterly revenues of $2.2M. Rockwell Medical, Inc.'s net income of -$1.8M is lower than Nuwellis, Inc.'s net income of $468K. Notably, Rockwell Medical, Inc.'s price-to-earnings ratio is -- while Nuwellis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rockwell Medical, Inc. is 0.37x versus 0.55x for Nuwellis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RMTIRockwell Medical, Inc.0.37x -- $15.9M -$1.8M NUWENuwellis, Inc.0.55x -- $2.2M $468K
-
Which has Higher Returns RMTI or PAVM?
PAVmed, Inc. has a net margin of -11.01% compared to Rockwell Medical, Inc.'s net margin of -120220%. Rockwell Medical, Inc.'s return on equity of -17.16% beat PAVmed, Inc.'s return on equity of 8.75%.
Company Gross Margin Earnings Per Share Invested Capital RMTIRockwell Medical, Inc.14.27% -$0.05 $50.1M PAVMPAVmed, Inc.-1440% -$0.29 $35.1M -
What do Analysts Say About RMTI or PAVM?
Rockwell Medical, Inc. has a consensus price target of $3.75, signalling upside risk potential of 363.36%. On the other hand PAVmed, Inc. has an analysts' consensus of $9.50 which suggests that it could grow by 3204.35%. Given that PAVmed, Inc. has higher upside potential than Rockwell Medical, Inc., analysts believe PAVmed, Inc. is more attractive than Rockwell Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RMTIRockwell Medical, Inc.1 0 0 PAVMPAVmed, Inc.1 0 0 -
Is RMTI or PAVM More Risky?
Rockwell Medical, Inc. has a beta of 1.621, which suggesting that the stock is 62.123% more volatile than S&P 500. In comparison PAVmed, Inc. has a beta of 1.095, suggesting its more volatile than the S&P 500 by 9.503%.
-
Which is a Better Dividend Stock RMTI or PAVM?
Rockwell Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PAVmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rockwell Medical, Inc. pays -- of its earnings as a dividend. PAVmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RMTI or PAVM?
Rockwell Medical, Inc. quarterly revenues are $15.9M, which are larger than PAVmed, Inc. quarterly revenues of $5K. Rockwell Medical, Inc.'s net income of -$1.8M is higher than PAVmed, Inc.'s net income of -$6M. Notably, Rockwell Medical, Inc.'s price-to-earnings ratio is -- while PAVmed, Inc.'s PE ratio is 0.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rockwell Medical, Inc. is 0.37x versus 256.11x for PAVmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RMTIRockwell Medical, Inc.0.37x -- $15.9M -$1.8M PAVMPAVmed, Inc.256.11x 0.30x $5K -$6M
-
Which has Higher Returns RMTI or TLSI?
TriSalus Life Sciences, Inc. has a net margin of -11.01% compared to Rockwell Medical, Inc.'s net margin of -93.47%. Rockwell Medical, Inc.'s return on equity of -17.16% beat TriSalus Life Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RMTIRockwell Medical, Inc.14.27% -$0.05 $50.1M TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M -
What do Analysts Say About RMTI or TLSI?
Rockwell Medical, Inc. has a consensus price target of $3.75, signalling upside risk potential of 363.36%. On the other hand TriSalus Life Sciences, Inc. has an analysts' consensus of $11.50 which suggests that it could grow by 62.89%. Given that Rockwell Medical, Inc. has higher upside potential than TriSalus Life Sciences, Inc., analysts believe Rockwell Medical, Inc. is more attractive than TriSalus Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RMTIRockwell Medical, Inc.1 0 0 TLSITriSalus Life Sciences, Inc.6 0 0 -
Is RMTI or TLSI More Risky?
Rockwell Medical, Inc. has a beta of 1.621, which suggesting that the stock is 62.123% more volatile than S&P 500. In comparison TriSalus Life Sciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RMTI or TLSI?
Rockwell Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TriSalus Life Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rockwell Medical, Inc. pays -- of its earnings as a dividend. TriSalus Life Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RMTI or TLSI?
Rockwell Medical, Inc. quarterly revenues are $15.9M, which are larger than TriSalus Life Sciences, Inc. quarterly revenues of $11.6M. Rockwell Medical, Inc.'s net income of -$1.8M is higher than TriSalus Life Sciences, Inc.'s net income of -$10.8M. Notably, Rockwell Medical, Inc.'s price-to-earnings ratio is -- while TriSalus Life Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rockwell Medical, Inc. is 0.37x versus 5.80x for TriSalus Life Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RMTIRockwell Medical, Inc.0.37x -- $15.9M -$1.8M TLSITriSalus Life Sciences, Inc.5.80x -- $11.6M -$10.8M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
